<br>基于双肿瘤外泌体生物标志物联合识别的纳米液体活检用于胰腺癌的准确早期诊断,ACS Nano

当前位置： X-MOL 学术 › ACS Nano › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

基于双肿瘤外泌体生物标志物联合识别的纳米液体活检用于胰腺癌的准确早期诊断
ACS Nano ( IF 15.8 ) Pub Date : 2023-06-08 , DOI: 10.1021/acsnano.3c00674
Zhiguo Yu _{1,

2} , Yang Yang ₃ , Wenming Fang _{1,

2} , Ping Hu _{1,

4} , Yingbin Liu ₃ , Jianlin Shi _{1,

2,

4}

Affiliation

胰腺癌的治疗选择极为有限，预后较差，迫切需要在早期诊断和监测方面取得突破。肿瘤外泌体（T-Exos）检测是目前用于非侵入性胰腺癌早期诊断的最具临床意义的液体活检方法之一，不幸的是，直到存在一些障碍（例如特异性不令人满意）之前，该方法无法作为常规诊断工具应用克服了灵敏度以及通过超速离心和酶联免疫吸附测定进行的劳动密集型纯化和分析程序。在这里，我们报告了一种简便的纳米液体活检测定法，通过双特异性生物标志物抗原共同识别和捕获策略进行特别特异性、超灵敏且经济的 T-Exos 检测，该策略是通过在磁性纳米颗粒和金纳米颗粒上嫁接两种相应的捕获抗体来实现的，用于准确检测靶肿瘤外泌体。该方法表现出优异的特异性和超高灵敏度，可检测低至 78 pg/mL 的胰腺癌外泌体特异性蛋白 GPC1。从22个正常对照病例中成功筛查出21个胰腺癌样本，并提高了特异性和敏感性，确保了早期胰腺癌的无创监测和诊断有希望。

"点击查看英文标题和摘要"

Dual Tumor Exosome Biomarker Co-recognitions Based Nanoliquid Biopsy for the Accurate Early Diagnosis of Pancreatic Cancer

Pancreatic cancer, with extremely limited treatment options and poor prognosis, urgently needs a breakthrough in early diagnosis and monitoring. Tumor exosomes (T-Exos) detection is presently one of the most clinically significant liquid biopsy approaches for non-invasive pancreatic cancer early diagnosis, which, unfortunately, cannot be applied as a routine diagnostic tool until a number of obstacles, such as unsatisfactory specificity and sensitivity, as well as labor-intensive purification and analysis procedures by ultracentrifugation and enzyme-linked immunosorbent assay, are overcome. Here, we report a facile nanoliquid biopsy assay for the especially specific, ultrasensitive yet economical T-Exos detection by a dual specific biomarker antigen co-recognition and capturing strategy, which is enabled by grafting two corresponding capture antibodies on magnetic nanoparticles and gold nanoparticles, for the accurate detection of target tumor exosomes. This approach exhibits excellent specificity and ultrahigh sensitivity of detecting as low as 78 pg/mL pancreatic cancer exosome specific protein GPC1. Successful screening of 21 pancreatic cancer samples from 22 normal control cases with the enhanced specificity and sensitivity ensures the promising non-invasive monitoring and diagnosis for early stage pancreatic cancer.

更新日期：2023-06-08

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南